Halozyme Therapeutics (NASDAQ:HALO) Director Sells $150,480.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total value of $150,480.00. Following the completion of the transaction, the director directly owned 44,952 shares of the company’s stock, valued at approximately $3,382,188.48. This trade represents a 4.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Bernadette Connaughton also recently made the following trade(s):

• On Tuesday, September 2nd, Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $73.68, for a total value of $294,720.00.

Halozyme Therapeutics Stock Down 3.8%

HALO stock opened at $68.98 on Friday. The company has a market cap of $8.07 billion, a PE ratio of 15.78, a price-to-earnings-growth ratio of 0.40 and a beta of 1.16. The business has a 50-day simple moving average of $70.45 and a 200 day simple moving average of $61.97. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $79.50. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 2nd. The Goldman Sachs Group assumed coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They set a “neutral” rating and a $55.00 target price for the company. JMP Securities boosted their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Halozyme Therapeutics in a research note on Saturday, September 27th. Finally, JPMorgan Chase & Co. boosted their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $70.44.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of HALO. DLD Asset Management LP purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at $650,250,000. Arrowstreet Capital Limited Partnership raised its position in Halozyme Therapeutics by 127.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after buying an additional 1,425,674 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at $51,295,000. Los Angeles Capital Management LLC raised its position in Halozyme Therapeutics by 951.8% in the 2nd quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company’s stock valued at $50,650,000 after buying an additional 881,094 shares during the last quarter. Finally, Norges Bank purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at $45,027,000. 97.79% of the stock is owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.